Pfizer (PFE) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competition for a few years. However, there are several competitors that have already received approval for a disease closely similar to ATTR-CM. This remains as a major risk to potential sales for both Vyndaqel and Vyndamax.
FDA Approval Puts Company In Good Position
The FDA